Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodacif is a consumer health supplement developed by Stragen Pharma Group, specifically formulated for women during the preconception period, pregnancy, and lactation. It consists of a combination of iodine and folic acid (Vitamin B9). The supplement is designed to prevent nutritional deficiencies that are critical for maternal health and fetal development. Folic acid is essential for DNA synthesis and cell division, significantly reducing the risk of neural tube defects (NTDs) in the developing fetus. Iodine is a vital component for the synthesis of thyroid hormones, which are necessary for the regulation of metabolism and the proper development of the fetal central nervous system. Iodacif is typically administered as a daily oral tablet to ensure adequate intake of these two micronutrients during periods of increased physiological demand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodacif.